Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 801–900 of 1,003
Discovery and optimization of covalent Bcl-xL antagonists
Mukherjee, H., Su, N., Belmonte, M. A., Hargreaves, D., Patel, J. S., Tentarelli, S., Aquila, B. M., & Grimster, N. P. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126682 · Cited by 23
Strizhak, A. V., Babii, O., Afonin, S., Bakanovich, I., Panteļejevs, T., Xu, W., Fowler, E., Eapen, R., Sharma, K., Platonov, M. O., et al. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00831a · Cited by 26
New small molecule inhibitors of hepatitis C virus
Wei, W., Cai, C., Kota, S., Takahashi, V., Ni, F., Strosberg, A. D., & Snyder, J. K. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.070 · Cited by 22
Hu, Y., Li, S., Liu, F., Geng, L., Shu, X. H., & Zhang, J. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.08.050 · Cited by 24
Assessment of the Mitotic Spindle Assembly Checkpoint (SAC) as the Target of Anticancer Therapies
Bolaños-García, V. M. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787580980 · Cited by 22
Xu, J., & Fang, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1854220 · Cited by 22
Kwon, H. S., Kim, D.-R., Yang, E. G., Park, Y. K., Ahn, H.-C., Min, S.-J., & Ahn, D.-R. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.06.054 · Cited by 21
Dever, S. M., White, E. R., Hartman, M. C. T., & Valerie, K. C. (2012) · Cell Cycle · doi:10.4161/cc.11.4.19212 · Cited by 26
Heterogeneous information network and its application to human health and disease
Ding, P., Ouyang, W., Luo, J., & Kwoh, C.-K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz091 · Cited by 23
Fragment-based drug discovery and protein–protein interactions
Turnbull, A. P., Boyd, S., & Walse, B. (2014) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s28428 · Cited by 29
Tzakos, A. G., Fokas, D., Johannes, C., Moussis, V., Hatzimichael, E. C., & Briasoulis, E. C. (2011) · Molecules · doi:10.3390/molecules16064408 · Cited by 23
“Such observations have recently challenged the traditional thought that PPIs are “undruggable” targets and numerous smallmolecule inhibitors of PPIs are now in clinical trials [48,61].”
BackgroundFragment library design considerations
Boyd, S. M., Turnbull, A. P., & Walse, B. (2012) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1098 · Cited by 21
Zinc(II)cyclen–peptide conjugates interacting with the weak effector binding state of Ras
Schmidt, F., Rosnizeck, I. C., Spoerner, M., Kalbitzer, H. R., & König, B. (2010) · Inorganica Chimica Acta · doi:10.1016/j.ica.2010.07.067 · Cited by 27
Selective Protein−Protein Interactions Driven by a Phenylalanine Interface
Yoder, N. C., & Kumar, K. (2005) · Journal of the American Chemical Society · doi:10.1021/ja055494k · Cited by 22
Martín‐Quirós, A., Nevola, L., Eckelt, K., Madurga, S., Gorostiza, P., & Giralt, E. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.10.022 · Cited by 22
A Highly Potent and Cellularly Active β‐Peptidic Inhibitor of the p53/hDM2 Interaction
Hintersteiner, M., Kimmerlin, T., Garavel, G., Schindler, T., Bauer, R., Meisner-Kober, N. C., Seifert, J., Uhl, V., & Auer, M. (2009) · ChemBioChem · doi:10.1002/cbic.200800803 · Cited by 21
Howl, J., & Jones, S. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2014.24 · Cited by 26
Wang, C., Wang, J., & Deng, L. (2011) · Nanoscale Research Letters · doi:10.1186/1556-276x-6-579 · Cited by 21
“This is particularly important in drug discovery and the computer-aided drug design (CADD) method has identified molecules modifying protein-protein interactions as potential drug candidates [8,9].”
Targeting synuclein-γ to counteract drug resistance in cancer
Singh, V. K., & Jia, Z. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.1.59 · Cited by 21
“Still, developing small-molecule antagonists of protein–protein interactions is challenging, due to the general lack of available small-molecule starting points for rationale drug design [80] .”
BackgroundSchormann, N., Sommers, C. I., Prichard, M. N., Keith, K. A., Noah, J. W., Nuth, M., Ricciardi, R. P., & Chattopadhyay, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00278-11 · Cited by 21
“Therapeutic applications of PPI inhibitors are wide ranging (1, 3, 10).”
BackgroundDiversity-Oriented Synthesis of a Library of Star-Shaped 2H-Imidazolines
Yu, X., Guttenberger, N., Fuchs, E., Peters, M., Weber, H., & Breinbauer, R. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00107 · Cited by 22
Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein
Li, Q., Ma, L., Yi, D., Wang, H., Wang, J., Zhang, Y., Guo, Y., Li, X., Zhou, J., Shi, Y., et al. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.04.020 · Cited by 21
Decoding Protein-protein Interactions: An Overview
Slater, O., Miller, B., & Kontoyianni, M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200226105312 · Cited by 23
Berwanger, A., Eyrisch, S., Schuster, I., Helms, V., & Bernhardt, R. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.10.007 · Cited by 22
Schrader, T. H. (2012) · Nature Chemistry · doi:10.1038/nchem.1386 · Cited by 21
Poondra, R. R., Kumar, N., Bijian, K., Prakesch, M. A., Campágna‐Slater, V., Reayi, A., Reddy, P. T., Choudhry, A., Barnes, M. L., Leek, D. M., et al. (2009) · Journal of Combinatorial Chemistry · doi:10.1021/cc8001525 · Cited by 21
Small-molecule control of cytokine function: new opportunities for treating immune disorders
Sundberg, T. B., Xavier, R. J., Schreiber, S. L., & Shamji, A. F. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.08.013 · Cited by 21
“IL-2/IL-2R SP-4206 and others [74] Inhibit IL-2 binding to IL-2R [75] Pre-clinical”
BackgroundPotent inhibitors of hepatitis C core dimerization as new leads for anti-hepatitis C agents
Ni, F., Kota, S., Takahashi, V., Strosberg, A. D., & Snyder, J. K. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.014 · Cited by 21
Hot-spot analysis to dissect the functional protein-protein interface of a tRNA-modifying enzyme
Jakobi, S., Nguyen, T. X. P., Debaene, F., Metz, A., Cianférani, S., Reuter, K., & Klebe, G. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24637 · Cited by 22
Park, H. R., Cockrell, L. M., Du, Y., Kasinski, A. L., Havel, J. J., Zhao, J., Reyes‐Turcu, F. E., Wilkinson, K. D., & Fu, H. (2008) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-60327-375-6_30 · Cited by 22
Jakobi, S., Nguyen, P. T. X., Debaene, F., Cianférani, S., Reuter, K., & Klebe, G. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00028 · Cited by 22
Targeting transcription factors in cancer: Challenges and evolving strategies
Redell, M. S., & Tweardy, D. J. (2006) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2006.09.010 · Cited by 24
The protein network as a tool for finding novel drug targets
Strong, M., & Eisenberg, D. S. (2007) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7567-6_8 · Cited by 28
Silva, F. D., Bret, G., Teixeira, L. D., González, C. F., & Rognan, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01184 · Cited by 21
Buchwald, P. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.898035 · Cited by 21
Selection of Peptide–Bismuth Bicycles Using Phage Display
He, R.-N., Zhang, M.-J., Dai, B., & Kong, X. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00099 · Cited by 20
Expanding the concepts and tools of metabolic engineering to elucidate cancer metabolism
Keibler, M. A., Fendt, S., & Stephanopoulos, G. N. (2012) · Biotechnology Progress · doi:10.1002/btpr.1629 · Cited by 27
Wang, G., MacRaild, C. A., Mohanty, B., Mobli, M., Cowieson, N. P., Anders, R. F., Simpson, J. S., McGowan, S., Norton, R. S., & Scanlon, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109674 · Cited by 20
“This is especially critical for targeting protein-protein interactions (PPIs) [31].”
BackgroundOligomeric-Induced Activity by Thienyl Pyrimidine Compounds Traps Prion Infectivity
Ayrolles-Torro, A., Imberdis, T., Torrent, J., Toupet, K., Baskakov, I. V., Poncet-Montange, G., Gregoire, C. J., Roquet, F., Lehmann, S., Rognan, D., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0547-11.2011 · Cited by 20
“Crystal structure studies have revealed that, in the case of globular proteins, small molecules act directly through the plasticity of the interface or allosterically by inducing conformational changes at distant sites (Arkin and Wells, 2004); thus, we first determined by molecular modeling whether we could identify a…”
BackgroundOn the Role of Flexibility in Protein–Ligand Interactions: the Example of p53 Tetramerization Domain
Gordo, S., Martos, V., Vilaseca, M., Menéndez, M., de Mendoza, J., & Giralt, E. (2011) · Chemistry - An Asian Journal · doi:10.1002/asia.201000938 · Cited by 21
Entropically driven Polymeric Enzyme Inhibitors by End‐Group directed Conjugation
Hijazi, M., Krumm, C., Cinar, S., Arns, L., Alachraf, W., Hiller, W., Schräder, W., Winter, R., & Tiller, J. C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201800168 · Cited by 20
Sun, H., Chen, D., Zhan, S., Wu, W., Xu, H., Luo, C., Su, H., Feng, Y., Shao, W., Wan, A. H., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01262 · Cited by 22
Javanmard, M., Babrzadeh, F., & Davis, R. W. (2010) · Applied Physics Letters · doi:10.1063/1.3491547 · Cited by 21
Kleine Moleküle als Transkriptionsmodulatoren
Arndt, H. (2006) · Angewandte Chemie · doi:10.1002/ange.200600285 · Cited by 20
N-Linked Peptidoresorc[4]arene-Based Receptors as Noncompetitive Inhibitors for α-Chymotrypsin
D’Acquarica, I., Cerreto, A., Monache, G. D., Subrizi, F., Boffi, A., Tafi, A., Forli, S., & Botta, B. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo102592f · Cited by 20
The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides
Kumar, E. A., Chen, Q., Kizhake, S., Kolar, C., Kang, M., Chang, C. A., Borgstahl, G. E. O., & Natarajan, A. (2013) · Scientific Reports · doi:10.1038/srep01639 · Cited by 22
Spérandio, O., Miteva, M. A., Segers, K., Nicolaes, G. A. F., & Villoutreix, B. O. (2008) · The Open Biochemistry Journal · doi:10.2174/1874091x00802010029 · Cited by 23
CD80 Binding Polyproline Helical Peptide Inhibits T Cell Activation
Srinivasan, M., Lu, D., Eri, R. D., Brand, D. D., Haque, A., & Blum, J. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409521200 · Cited by 20
Nissen, K. B., Haugaard‐Kedström, L. M., Wilbek, T. S., Nielsen, L., Åberg, E., Kristensen, A. S., Bach, A., Jemth, P., & Strømgaard, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117668 · Cited by 24
“Protein-protein interactions (PPIs) are vital for almost all cellular and biochemical processes and have attracted particular attention due to their potential as novel and promising drug targets for the treatment of several disease states.[1,2] The postsynaptic density protein-95 (PSD-95), discs large, zona occludens…”
BackgroundIdentification of Potential Small Molecule Peptidomimetics Similar to Motifs in Proteins
Baran, I., Vařeková, R. S., Parthasarathi, L., Suchomel, Š., Casey, F., & Shields, D. C. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600404q · Cited by 20
Hayes, M. P., & Roman, D. L. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9894-1 · Cited by 20
Wang, Z., Xu, W., Song, T., Guo, Z., Liu, L., Fan, Y., Wang, A., & Zhang, Z. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201600251 · Cited by 20
Ren, X., Zeng, R., Tortorella, M. D., Wang, J., & Wang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14916-6 · Cited by 20
Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors
Li, B., Rong, D., & Wang, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191011163410 · Cited by 22
Halim, S. A., & Ul‐Haq, Z. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.05.018 · Cited by 20
“Clinical data with antibodies directed against IL-2Ra suggest that specific inhibition of IL2/IL-2Ra interaction targets the Th1 response without causing toxicity which has been observed with general immune-modulators [9,10].”
BackgroundProtein Promiscuity: Drug Resistance and Native Functions—HIV-1 Case
Fernández, A., Tawfik, D. S., Berkhout, B., Sanders, R. W., Kloczkowski, A., Sen, T. Z., Jernigan, B., Tawfik, D. S., Berkhout, B., Sanders, R. W., et al. (2005) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2005.10531228 · Cited by 20
Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity
Wen, W., Wang, W., & Zhang, M. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776894474 · Cited by 21
Generation of three‐dimensional pharmacophore models
Drie, J. H. V. (2012) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1129 · Cited by 20
“58 One way to do this is via clustering docking results (as shown in Figure 10), 59 which indirectly indicates which sites are likely contributing a disproportionate amount to the overall binding affinity.”
BackgroundThe Centrosome: A Target for Cancer Therapy
Mazzorana, M., Montoya, G., & Mortuza, G. B. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795655949 · Cited by 19
Ginex, T., Muñoz, J. A., Herrero, E., Gibert, E., Cozzini, P., & Luque, F. J. (2016) · Journal of Computational Chemistry · doi:10.1002/jcc.24305 · Cited by 19
Trisciuzzi, D., Villoutreix, B. O., Siragusa, L., Baroni, M., Cruciani, G., & Nicolotti, O. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2218641 · Cited by 22
“LMW PPI modulators are crucial to understand protein-protein recognition [32,147].”
BackgroundTarr, J. C., Salovich, J. M., Aichinger, M., Jeon, K., Veerasamy, N., Sensintaffar, J., Arnhof, H., Samwer, M., Christov, P. P., Kim, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01188 · Cited by 25
Ding, X., Li, Y., Lv, L., Zhou, M., Han, L., Zhang, Z., Ba, Q., Li, J., Wang, H., Liu, H., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300316 · Cited by 19
Recognition and Modulation of Cytochrome c's Redox Properties using an Amphiphilic Homopolymer
Sandanaraj, B. S., Bayraktar, H., Krishnamoorthy, K., Knapp, M. J., & Thayumanavan, S. (2007) · Langmuir · doi:10.1021/la063063p · Cited by 19
Analysis of Protein Complex Hierarchy in Living Cells
Piljić, A., & Schultz, C. (2008) · ACS Chemical Biology · doi:10.1021/cb8002539 · Cited by 19
Modulation of the FGF14:FGF14 Homodimer Interaction Through Short Peptide Fragments
Ali, S. R., Shavkunov, A. S., Panova, N. I., Stoilova‐McPhie, S., & Laezza, F. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141126103309 · Cited by 20
Facile Iterative Synthesis of 2,5-Terpyrimidinylenes as Nonpeptidic α-Helical Mimics
Anderson, L. C., Zhou, M., Sharma, V., McLaughlin, J. M., Santiago, D. N., Fronczek, F. R., Guida, W. C., & McLaughlin, M. L. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo100272d · Cited by 19
Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin
Zhao, B., Sensintaffar, J., Bian, Z., Belmar, J., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.060 · Cited by 22
“Mcl-1 mediates its effects primarily through a protein-protein interaction and is difficult to target with small molecules.(7)”
Jana, T., Ghosh, A., Mandal, S. D., Banerjee, R., & Saha, S. (2017) · Royal Society Open Science · doi:10.1098/rsos.160501 · Cited by 19
Gavriilidou, A. F. M., Holding, F. P., Coyle, J. E., & Zenobi, R. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218775921 · Cited by 22
Cysteine modifiers suggest an allosteric inhibitory site on the CAL PDZ domain
Zhao, Y., Cushing, P. R., Smithson, D. C., Pellegrini, M., Pletnev, A. A., Al-Ayyoubi, S., Grassetti, A. V., Gerber, S. A., Guy, R. K., & Madden, D. R. (2018) · Bioscience Reports · doi:10.1042/bsr20180231 · Cited by 20
Farzaneh, M., Derakhshan, Z., Hallajzadeh, J., Sarani, N. H., Nejabatdoust, A., & Khoshnam, S. E. (2019) · Current Stem Cell Research & Therapy · doi:10.2174/1871527318666190314110529 · Cited by 19
da Silva, F. D., Nogara, P. A., Ochoa, E., Núñez-Figueredo, Y., Wong-Guerra, M., Rosemberg, D. B., & da Rocha, J. B. T. (2019) · Biochimie · doi:10.1016/j.biochi.2019.11.011 · Cited by 20
Shao, H., Oltion, K., Wu, T., & Gestwicki, J. E. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob00928h · Cited by 20
Single-molecule analysis of interaction between p53TAD and MDM2 using aerolysin nanopores
Oh, S., Lee, M., & Chi, S. (2021) · Chemical Science · doi:10.1039/d1sc00386k · Cited by 19
A System for the Evolution of Protein–Protein Interaction Inducers
Dewey, J. A., Azizi, S., Lu, V., & Dickinson, B. C. (2021) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00276 · Cited by 19
New Aβ(1–42) ligands from anti-amyloid antibodies: Design, synthesis, and structural interaction
Santoro, A., Grimaldi, M., Buonocore, M., Stillitano, I., Gloria, A., Santin, M., Bobba, F., Saponetti, M. S., Ciaglia, E., & D’Ursi, A. M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114400 · Cited by 20
Chuang, S.-T., Papp, H., Kuczmog, A., Eells, R., Capcha, J. M. C., Shehadeh, L. A., Jakab, F., & Buchwald, P. (2022) · Pharmaceuticals · doi:10.3390/ph15050621 · Cited by 21
Development of E3‐Substrate (MDM2‐p53)–Binding Inhibitors: Structural Aspects
Fry, D. C., Graves, B. J., & Vassilev, L. T. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99041-1 · Cited by 19
Vassiliou, S., & Magriotis, P. Α. (2006) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2006.06.019 · Cited by 20
Zawahir, Z., & Neamati, N. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.07.022 · Cited by 21
Structural Characterizations of Oligopyridyl Foldamers, α-Helix Mimetics
Santos, J. S. O., Voisin‐Chiret, A. S., Burzicki, G., Sebaoun, L., Sebban, M., Lohier, J., Legay, R., Oulyadi, H., Bureau, R., & Rault, S. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200424a · Cited by 19
Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches
Schomberg, D. T., Miranpuri, G. S., Duellman, T., Crowell, A. D., Vemuganti, R., & Resnick, D. K. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-014-9642-0 · Cited by 20
“Endothelial WNT/ β-catenin signaling regulates induction and maintenance of blood brain barrier characteristics during embryonic and postnatal development and its inactivation is associated with decreased BBB integrity (Liebner et al. 2008).”
BackgroundSurface Binding Inhibitors of the SCF–KIT Protein–Protein Interaction
Margulies, D. H., Opatowsky, Y., Fletcher, S., Saraogi, I., Tsou, L. K., Saha, S., Lax, I., Schlessinger, J., & Hamilton, A. D. (2009) · ChemBioChem · doi:10.1002/cbic.200900079 · Cited by 19
Tran, H. N. A., Bongarzone, S., Carloni, P., Legname, G., & Bolognesi, M. L. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.149 · Cited by 19
Synthesis and Structural Investigations of Functionalizable Hybrid β-Hairpin
Bandyopadhyay, A., Mali, S. M., Lunawat, P., Raja, K. M. P., & Gopi, H. N. (2011) · Organic Letters · doi:10.1021/ol201840p · Cited by 21
Computational alanine scanning with linear scaling semiempirical quantum mechanical methods
Diller, D., Humblet, C. C., Zhang, X., & Westerhoff, L. M. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22745 · Cited by 19
Mining association rules from HIV-human protein interactions
Mukhopadhyay, A., Maulik, U., Bandyopadhyay, S., & Eils, R. (2010) · International Conference on Systems in Medicine and Biology (ICSMB) · doi:10.1109/icsmb.2010.5735401 · Cited by 19
“Targeting protein-protein interactions has relatively recently been established to be a promising alternative to the conventional approach to drug design [2], [ 3 ].”
MethodMathematical modeling of cyclic treatments of chronic myeloid leukemia
Komarova, N. L., & Komarova, N. L. (2011) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2011.8.289 · Cited by 19
Desrosiers, D. C., & Peng, Z.-Y. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.045 · Cited by 24
At The Interface: Small-Molecule Inhibitors of Soluble Cytokines
Raavi, Koehler, A. N., & Vegas, A. J. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00469 · Cited by 19
Multivalent helix mimetics for PPI-inhibition
Barnard, A., Miles, J. A., Burslem, G. M., Barker, A., & Wilson, A. J. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02066a · Cited by 22
Computational chemistry approaches to drug discovery in signal transduction
Fischer, P. M. (2008) · Biotechnology Journal · doi:10.1002/biot.200700259 · Cited by 23
“This example concerns an allosteric binding site which is adventitious insofar as it does not appear to have a native ligand (such sites are also referred to as cryptic binding sites), but adaptivity is a general phenomenon and occurs not only in protein interaction sites (which have been particularly refractory to ra…”
BackgroundAeluri, M., Pramanik, C., Chetia, L., Mallurwar, N. K., Sridhar, B., Chandrasekar, G., Kitambi, S. S., & Arya, P. (2013) · Organic Letters · doi:10.1021/ol3032126 · Cited by 18
Bender, A., Mikhailov, D., Glick, M., Scheiber, J., Davies, J. W., Cleaver, S. H., Marshall, S., Tallarico, J. A., Harrington, E. M., Cornella‐Taracido, I., et al. (2009) · Journal of Proteome Research · doi:10.1021/pr900107z · Cited by 18
Moore, C. D., Wu, H., Bolaños, B., Bergqvist, S., Brooun, A., Pauly, T., & Nowlin, D. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00862.x · Cited by 20
“faces are generally flat and often dynamic (28,29); in some cases, the dynamics facilitate the ability to bind to multiple partners, as”
BackgroundProtein-Protein Interaction Inhibition (2P2I): Fewer and Fewer Undruggable Targets
Betzi, S., Guerlesquin, F., & Morelli, X. (2009) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620709789824736 · Cited by 18
Dias, R., & Kolazckowski, B. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24928 · Cited by 19
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Wendt, M. D. (2012) · Topics in medicinal chemistry · doi:10.1007/978-3-642-28965-1_7 · Cited by 18
Ventosa‐Andrés, P., Hradilová, L., & Krchňák, V. (2014) · ACS Combinatorial Science · doi:10.1021/co500023k · Cited by 19
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.